CEOCAST AND MICHAEL WACHS ProLink Holdings Corp. (OTCBB: PLKH), the world's leading provider of Global Positioning Satellite golf course management systems and on-course advertising, reported strong preliminary fourth-quarter revenue for the period ended December 31, 2007. PLKH had record Q4 revenue which was in excess of $6.0 million, a significant increase compared to the same period in fiscal 2006 when the company had revenue of approximately $3.8 million. The fourth quarter is seasonally a slower period for the company as many of the golf courses in the Eastern and Midwestern parts of the country are closed. Gross margin of approximately 52% for the period was up over 100% as compared to the fiscal 2006 fourth quarter. A significant increase in new system sales and upgrades, advertising revenues and greater adoption of the ProLink System contributed to the higher revenue and improved profitability. The company also said that Arcadia Bluffs Golf Club now features the ProLink Solutions ProStar GPS system used at many of the world's most famous golf courses. The system will be extremely helpful in managing the cart fleet and keeping pace of play moving. In fact, The stock remained unchanged for the week at $0.55. MICHAEL WACHS PROFILE CEL-SCI Corporation (AMEX: CVM), a company that engages in the research and development of drugs and vaccines used in the treatment of cancer, announced the discovery of a novel peptide for the treatment of rheumatoid arthritis. This peptide, called CEL-2000, was tested in a well established animal model of rheumatoid arthritis and was compared to Enbrel, a leading treatment for people with rheumatoid arthritis. The tests showed that CEL-2000 is equivalent or possibly superior to Enbrel in slowing disease progression and lessening symptoms in mice. In addition, the vaccine has the potential to require fewer and smaller doses, be less toxic, more disease specific and much less invasive. The company also believes that the drug could be attractive to patients who are not able to take or be responsive to Enbrel, Remicade or Humira. Rheumatoid arthritis treatments comprise a $13 billion market. The stock rose by a penny, to finish the week at $0.67. MICHAEL WACHS CEOCAST INC

michael wachs, ceocast and michael wachs, ceocast